The Inflammatory Diseases Market is on the rise! Valued at $22.5B in 2025, it's projected to hit $34.9B by 2035 with a 4.5% CAGR. Asthma leads the pack, while North America, APAC & Europe drive growth. Powered by giants like AbbVie, Pfizer, Novartis & J&J—this market’s momentum is unstoppable! 🚀💼 Get More Info:- https://www.futuremarketinsights.com/reports/inflammatory-diseases-market

🧠 The Alzheimer's Therapeutics Market is evolving fast! 🚀 With disease-modifying therapies, AI-powered R&D, and strategic partnerships, major players like Eisai, Novartis & AbbVie lead the charge. 🧬 Mid-tier firms & rising biotech stars are investing in next-gen treatments to slow cognitive decline. 🌍 Market to hit $4.28B soon—innovation is accelerating! Get Sample PDF:- https://www.futuremarketinsights.com/reports/sample/rep-gb-20808 Purchase Here to Get Full Report Access:- https://www.futuremarketinsights.com/checkout/20808 💊 #Alzheimers #Biotech #PharmaNews #Innovation #DrugDiscovery

The global Breast Cancer Therapy Market is witnessing significant momentum as innovative treatment approaches, rising disease awareness, and supportive healthcare policies converge to redefine patient outcomes. With an increasing number of breast cancer cases reported worldwide, the demand for effective diagnostic and therapeutic solutions continues to rise, driving rapid advancements in oncology treatment protocols. Market Overview The global Breast Cancer Therapy market size is expected to reach USD 63.13 billion by 2032, according to a new study by Polaris Market Research. The market encompasses a wide range of treatment modalities including chemotherapy, hormonal therapy, targeted therapy, immunotherapy, and radiation therapy. Key therapeutic innovations and rising investment in cancer research are accelerating market growth, with emerging players and established pharmaceutical companies launching new drug formulations and personalized treatments. Key Market Growth Drivers 1. Rising Global Incidence of Breast Cancer According to the World Health Organization (WHO), breast cancer has surpassed lung cancer as the most commonly diagnosed cancer globally. In 2024 alone, over 2.3 million women were diagnosed with breast cancer, making it a leading cause of cancer-related deaths among females. This soaring incidence is a primary driver of therapy demand, leading to increased screening programs and early detection initiatives. 2. Advancements in Targeted and Immunotherapies Breakthroughs in targeted therapy and cancer immunotherapy are transforming the treatment landscape. Medications like trastuzumab, pertuzumab, palbociclib, and newer checkpoint inhibitors offer improved efficacy and fewer side effects compared to traditional chemotherapy. The integration of biomarkers and companion diagnostics has further enhanced the precision of treatment delivery. 3. Government and Private Sector Investment Growing government support and private sector funding in oncology research and clinical trials are fueling the development of novel breast cancer drugs. Initiatives such as the Cancer Moonshot program in the United States and the EU’s Horizon Europe research funding have mobilized substantial resources for cancer therapy innovation. 4. Rising Awareness and Early Detection Campaigns Public health campaigns, advocacy by non-profits such as the Susan G. Komen Foundation and Breast Cancer Now, and corporate social responsibility initiatives are boosting awareness, reducing stigma, and encouraging early screening. Earlier diagnosis significantly improves treatment outcomes, thereby increasing the adoption of therapy solutions. 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞: https://www.polarismarketresearch.com/industry-analysis/breast-cancer-therapy-market Market Challenges Despite the growth trajectory, the breast cancer therapy market faces several obstacles: 1. High Treatment Costs Advanced therapies, particularly biologics and immunotherapies, come with high price tags. The cost burden poses challenges for patients in low-income regions and contributes to inequality in access to treatment. Even in developed economies, the affordability of newer therapies remains a concern for uninsured or underinsured populations. 2. Adverse Effects and Drug Resistance Chemotherapy and radiation therapy often lead to severe side effects, such as nausea, fatigue, and hair loss, affecting the patient’s quality of life. Additionally, drug resistance in metastatic breast cancer limits the long-term effectiveness of certain treatments, prompting the need for ongoing drug innovation and combination therapies. 3. Complex Regulatory Approvals Securing regulatory approvals for new cancer drugs involves rigorous clinical testing and time-intensive documentation. Delays in approval can restrict the timely introduction of promising treatments into the market. 4. Limited Access in Emerging Economies Healthcare infrastructure challenges in many developing countries, along with lack of trained oncologists and inadequate insurance coverage, limit the adoption of advanced breast cancer therapies in these regions. Regional Analysis North America North America holds the largest share of the global market, driven by high awareness, early diagnosis rates, and the availability of advanced healthcare infrastructure. The United States, in particular, is a dominant player, with strong R&D activity, a robust clinical trial pipeline, and the presence of major pharmaceutical companies like Pfizer, Roche, and Eli Lilly. Europe Europe is the second-largest market, with countries such as Germany, France, and the United Kingdom showing strong demand for targeted and hormonal therapies. Government-funded cancer research programs and national screening guidelines contribute to market expansion. Asia Pacific The Asia Pacific region is experiencing the fastest growth due to rising cancer prevalence, improved access to healthcare, and increased investment by global pharmaceutical companies. China, India, and Japan are emerging as high-potential markets, particularly in urban centers where awareness and healthcare access are improving. Latin America & Middle East These regions are gradually expanding due to enhanced health policies and international health aid. However, limited access to advanced therapies and diagnostic tools remains a hurdle. Key Companies in the Breast Cancer Therapy Market Several leading companies are at the forefront of innovation and market development: 1. Roche Holding AG Roche is a global leader in oncology, with a robust portfolio that includes Herceptin, Perjeta, and Kadcyla. The company continues to invest heavily in targeted therapies and personalized treatment approaches. 2. Pfizer Inc. Pfizer has significantly contributed to the breast cancer treatment space with drugs like Ibrance (palbociclib), a CDK 4/6 inhibitor that has changed the standard of care for HR-positive, HER2-negative metastatic breast cancer. 3. AstraZeneca AstraZeneca’s focus on precision oncology is evident in its pipeline of antibody-drug conjugates (ADCs) and the success of Enhertu, developed in partnership with Daiichi Sankyo. The company is also exploring combination therapies to overcome drug resistance. 4. Eli Lilly and Company Eli Lilly has expanded its oncology portfolio with Verzenio (abemaciclib), another CDK4/6 inhibitor that has shown promise in both early-stage and advanced breast cancer cases. 5. Novartis AG Novartis plays a major role with its Kisqali (ribociclib) and a deep research pipeline targeting hormone receptor-positive subtypes. The company emphasizes access programs in low- and middle-income countries. 6. Gilead Sciences Gilead entered the breast cancer therapy space through its acquisition of Immunomedics and its groundbreaking ADC, Trodelvy, targeting triple-negative breast cancer. Future Outlook The breast cancer therapy market is poised for transformative change as new technologies—including AI-driven diagnostics, genomic profiling, and nanotechnology-based drug delivery systems—gain traction. Moreover, as personalized medicine becomes more central to oncology treatment strategies, the focus will shift to tailored drug combinations, real-world evidence integration, and patient-centric care models. More Trending Latest Reports By Polaris Market Research: Hair Styling Products Market Guns and Accessories Market Hematologic Malignancies Therapeutics Market Thermal Spray Coatings Market Latin America Industrial Pumps Market Enteric Empty Capsules Market Snow Sport Accessories Market High Frequency Trading Servers Market Vascular Stent Market

CAR T Cell Therapy Market Emerging Trend, Opportunities, Key Players, Huge Growth, Revenue Analysis, 2023-2035 The latest report entitled ‘CAR T Cell Therapy Market’ by Roots Analysis provides an accurate estimation of the market size, regional landscape description, and revenue forecast over the projected timeframe. The current global CAR T-cell therapy market size is likely to be worth USD 4.6 billion, and is projected to reach worth USD 15.2 billion by 2035, growing at a CAGR of 11.4% during the period, till 2035. The report turns the spotlight on the major challenges faced by the key players in the global market and the growth strategies currently adopted by them. The report is a granular assessment of this particular business sphere and entirely covers the dynamic competitive landscape of the market. The document offers key insights into the market positions of these players alongside their gross earnings. Furthermore, it elaborates on each of the market segments, with detailed scrutiny of the development scope and competitive scenario of the regional fragments of the market. The latest study is inclusive of an in-depth analysis of the economic status of the CAR T Cell Therapy Market and examines the most important regions constituting the global market. It further details on the most lucrative and growth-oriented regions, top market rivals, diversified product types, and a large number of end-use industries. Key factors affecting the growth of the CAR T Cell Therapy Market: Geographical Overview: • The latest report broadly categorizes the CAR T Cell Therapy Market into several geographical terrains, including North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa and Rest of the World. • The study is inclusive of essential information relevant to each region in this broad industry segment, along with the key drivers of the regional market growth. • The report further estimates the revenue accumulated by these regions over the forecast period. Competitive Hierarchy: • The latest research report studies the major market players, their regional presence, industry share, and production facilities. • The report offers significant data pertaining to these market competitors’ company profiles, product types, and application outlook. • Moreover, the pricing models and gross margins of these industry majors have also been mentioned in the report. Key players Autolus, Bluebird Bio, Bristol Myers Squibb, Carsgen Therapeutics, Cellectis, Gilead Sciences, Innovative Cellular Therapeutics, Noile-Immune Biotech, Novartis, Shanghai GeneChem, Sinobioway Cell Therapy, Takara Bio and Wellington Zhaotai Therapies. Additional parameters of the CAR T Cell Therapy Market report: • The latest research study endows the reader with a comprehensive analysis of the product types of the CAR T Cell Therapy Market, categorizing the relevant information into the Distribution by Target Inidcation, Target Antigens and Key Geographical Regions. The study focuses on the wide-ranging application landscape of the market, segmenting it into the market share, estimated growth rate, and the forecast product demand for each application type. Additional Insights: • The market concentration rate and processing rate of raw materials have also been conscripted in the report. • The report contains an assessment of the current price trends, as well as the factors influencing the global market size. • It throws light on the significant marketing strategies implemented by the eminent players in the industry. • Vital data and information concerning the producers, distributors, and downstream buyers involved in the global market, as well as the cost structure analysis and market mechanism, form the important elements of this report. Research objectives: • The CAR T Cell Therapy Market report studies the worldwide market consumption rate in terms of value and volume. • It identifies the various sub-segments of the market structure. • It proffers information regarding the leading global manufacturers in this industry, describing their market value & share, sales volume, competitive analysis, SWOT analysis, and development strategies adopted during the forecast timeline. • The report describes the key industry players, with respect to their individual growth trends, future prospects, and contribution to the global market, and explains the factors related to their market growth potential, drivers, opportunities, threats, and industry-specific challenges. • Furthermore, the report underpins the strategic developments occurring in the CAR T Cell Therapy Market, such as expansions, mergers & acquisitions, agreements, as well as new product launches. To view more details on this report, click on the link https://www.rootsanalysis.com/reports/car-t-cell-therapy-market/269.html About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way. The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide. Contact: Roots Analysis +1 (415) 800 3415 Sales@rootsanalysis.com

Fill-finish Pharmaceutical Contract Market Global outlook 2024 to 2031 | Skyquest Leading market research firm SkyQuest Technology Group recently released a study titled 'Fill-finish Pharmaceutical Contract Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Fill-finish Pharmaceutical Contract report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Fill-finish Pharmaceutical Contract Market extensively demonstrates existing and upcoming opportunities, profitability, revenue growth rates, pricing, and scenarios for recent industry analysis. The research analysis on the global Fill-finish Pharmaceutical Contract Market report 2024 offers a close watch on top industry rivals along with briefings on their company profiles, strategical surveys, micro as well as macro industry trends, futuristic scenarios, analysis of pricing structure, and an all-encompassing overview of the Fill-finish Pharmaceutical Contract Market circumstances in the forecast period between 2024 and 2031. The global Fill-finish Pharmaceutical Contract Market is a dynamic and rapidly evolving sector, encompassing the development, production, and distribution. This market is essential for improving global market and driving economic growth through innovation and industry advancements. Market Growth The Fill-finish Pharmaceutical Contract Market has experienced robust growth over the past decade and is projected to continue expanding. In 2022, the global fill-finish pharmaceutical contract manufacturing market reached a significant value of USD 8.1 billion. Projections indicate that this market is poised for steady growth, with an estimated compound annual growth rate (CAGR) of 6.1% expected from 2024 to 2031. This growth is driven by several factors, including an aging global population, increasing prevalence of advancements in technology, and rising global expenditure. Chance to get a free sample @ https://www.skyquestt.com/sample-request/fill-finish-pharmaceutical-contract-manufacturing-market Detailed Segmentation and Classification of the report (Market Size and Forecast - 2031, Y-o-Y growth rate, and CAGR): The Fill-finish Pharmaceutical Contract Market can be segmented based on several factors, including product type, application, end-user, and distribution channel. Understanding these segments is crucial for companies looking to target specific markets and tailor their offerings to meet consumer needs. By Product Type - Prefilled Syringes, Vials, Cartridges, Others By Molecule Type - Large Molecules, Small Molecules By End-user - Biopharmaceutical Companies, Pharmaceutical Companies By Region - North America, Asia Pacific, Latin America, Europe Get your customized report @ https://www.skyquestt.com/speak-with-analyst/fill-finish-pharmaceutical-contract-manufacturing-market Following are the players analyzed in the report: AbbVie Inc. Boehringer Ingelheim Pfizer Catalent Inc Recro Pharma, Inc. Baxter’s BioPharma Solutions Eurofins Scientific Symbiosis Pharmaceutical Service MabPlex International Co. Ltd. Recipharm AB Fresenius Kabi Contract Manufacturing Novartis Regional Analysis 1. North America: - The United States and Canada dominate the North American Fill-finish Pharmaceutical Contract Market. The U.S. is the largest market globally, driven by advanced global infrastructure, high R&D investments, and significant Fill-finish Pharmaceutical Contract consumption. 2. Europe: - Europe is a significant player, with major Fill-finish Pharmaceutical Contract Markets in Germany, France, and the United Kingdom. The region benefits from strong regulatory frameworks, high industry standards, and a robust R&D sector. 3. Asia-Pacific: - This region is experiencing rapid growth, with countries like China and India leading the charge. Factors such as increasing industry access, growing middle-class populations, and expanding Fill-finish Pharmaceutical Contract manufacturing capabilities contribute to this growth. 4. Latin America: - Brazil and Mexico are key markets in Latin America. Growth in this region is driven by rising industry needs, increasing investments in industry infrastructure, and a growing demand for affordable medications. 5. Middle East and Africa: - The Fill-finish Pharmaceutical Contract Market in this region is expanding due to rising market spending, increased prevalence of diseases, and improvements in Market infrastructure, although the market is relatively smaller compared to other regions. Future Outlook The Fill-finish Pharmaceutical Contract Market is poised for continued growth driven by technological advancements, expanding global market access, and increasing global industry needs. As the industry adapts to evolving challenges and seizes emerging opportunities, it is likely to see ongoing innovation and expansion, contributing significantly to global health and economic development. Buy your full report: https://www.skyquestt.com/buy-now/fill-finish-pharmaceutical-contract-manufacturing-market

Oncology Market Rising Trends, Demand and Future Scope 2024 to 2031 Leading market research firm SkyQuest Technology Group recently released a study titled 'Oncology Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Oncology report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Oncology Market extensively demonstrates existing and upcoming opportunities, profitability, revenue growth rates, pricing, and scenarios for recent industry analysis. The research analysis on the global Oncology Market report 2024 offers a close watch on top industry rivals along with briefings on their company profiles, strategical surveys, micro as well as macro industry trends, futuristic scenarios, analysis of pricing structure, and an all-encompassing overview of the Oncology Market circumstances in the forecast period between 2024 and 2031. The global Oncology Market is a dynamic and rapidly evolving sector, encompassing the development, production, and distribution. This market is essential for improving global market and driving economic growth through innovation and industry advancements. Market Growth The Oncology Market has experienced robust growth over the past decade and is projected to continue expanding. Oncology Market size was valued at USD 286.04 billion in 2022 and is poised to grow from USD 309.3 billion in 2023 to USD 581.25 billion by 2031, growing at a CAGR of 8.2% in the forecast period (2024-2031). This growth is driven by several factors, including an aging global population, increasing prevalence of advancements in technology, and rising global expenditure. Chance to get a free sample @ https://www.skyquestt.com/sample-request/oncology-market Detailed Segmentation and Classification of the report (Market Size and Forecast - 2031, Y-o-Y growth rate, and CAGR): The Oncology Market can be segmented based on several factors, including product type, application, end-user, and distribution channel. Understanding these segments is crucial for companies looking to target specific markets and tailor their offerings to meet consumer needs. Cancer Diagnostics & Treatment Cancer Diagnostics {Tumor Biomarker Test, Imaging, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization}, Cancer Treatment {Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy} Cancer Type Lung Cancer, Prostate Cancer, Colon & Rectal Cancer, Gastric Cancer, Esophageal Cancer, Liver Cancer, Breast Cancer End-Use Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Academia, Specialty Clinics Get your customized report @ https://www.skyquestt.com/speak-with-analyst/oncology-market Following are the players analyzed in the report: Roche Holding AG Novartis International AG Bristol-Myers Squibb Company Pfizer Inc. Merck & Co., Inc. AstraZeneca PLC Johnson & Johnson Sanofi S.A. Takeda Pharmaceutical Company Limited Amgen Inc. AbbVie Inc. Eli Lilly and Company Gilead Sciences, Inc. Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company) Bayer AG Biogen Inc. Daiichi Sankyo Company, Limited Astellas Pharma Inc. Eisai Co., Ltd. Teva Pharmaceutical Industries Ltd. Regional Analysis 1. North America: - The United States and Canada dominate the North American Oncology Market. The U.S. is the largest market globally, driven by advanced global infrastructure, high R&D investments, and significant Oncology consumption. 2. Europe: - Europe is a significant player, with major Oncology Markets in Germany, France, and the United Kingdom. The region benefits from strong regulatory frameworks, high industry standards, and a robust R&D sector. 3. Asia-Pacific: - This region is experiencing rapid growth, with countries like China and India leading the charge. Factors such as increasing industry access, growing middle-class populations, and expanding Oncology manufacturing capabilities contribute to this growth. 4. Latin America: - Brazil and Mexico are key markets in Latin America. Growth in this region is driven by rising industry needs, increasing investments in industry infrastructure, and a growing demand for affordable medications. 5. Middle East and Africa: - The Oncology Market in this region is expanding due to rising market spending, increased prevalence of diseases, and improvements in Market infrastructure, although the market is relatively smaller compared to other regions. Future Outlook The Oncology Market is poised for continued growth driven by technological advancements, expanding global market access, and increasing global industry needs. As the industry adapts to evolving challenges and seizes emerging opportunities, it is likely to see ongoing innovation and expansion, contributing significantly to global health and economic development. Buy your full report: https://www.skyquestt.com/buy-now/oncology-market

Questo signore è Girolamo Sirchia, medico, politico e Ministro della salute dal 2001 al 2005 sotto il Governo Berlusconi. Del suo curriculum politico ci piace ricordare solo quanto segue: ✔️Il 2 febbraio 2005 è stato indagato per corruzione. ✔️Il 17 aprile 2008 è stato condannato in primo grado a tre anni di reclusione per tangenti nel mondo della sanità e appropriazione indebita, più cinque anni di interdizione dai pubblici uffici. Carcere scampato grazie all’indulto. ✔️Il 3 marzo 2010 la sentenza di appello ha confermato l'appropriazione indebita, ma ha ridotto la pena a 5 mesi di carcere e 600 € di multa. Successivamente la Corte d'Appello di Milano ha revocato anche l'interdizione dai pubblici uffici. Oltre a questo fantastico curriculum, del Dott. Sirchia ci interessano le doti paranormali visto che nel 2004, durante il secondo governo Berlusconi e mentre era Ministro della Salute, aveva contrattato con trattativa privata (cioè senza gara pubblica) un diritto di prelazione per l'acquisto di vaccini in caso di pandemia con l’azienda farmaceutica Novartis. Calcolate che non vi erano pandemie e l'aviaria appena passata avrebbe dovuto insegnare molto ai politici italici... Nel 2009 scoppiò (finalmente per qualcuno) la Pandemia di influenza Suina (A/H1N1) e indovinate quale fu il produttore del salvifico vaccino pandemico contro la Suina? Ma ovviamente Novartis! Successivamente furono mandate al macero 24 milioni di dosi. Chissà se tra qualche anno scopriremo un filo conduttore unico, che parte dall’Aviaria e arriva al Covid19… Corvelva Staff https://ansage.org/covid-impfschaeden-und-todesfaelle-sind-noch-lange-nach-der-impfung-moeglich/

L’Ordine dei Medici è corresponsabile dell’obbligo vaccinale e del degrado della professione medica Uno dei nodi emersi clamorosamente durante la pandemia è l’asservimento pressoché universale delle organizzazioni professionali mediche ai diktat del governo. Non tutti sanno che tale atteggiamento servile ha radici nell’era della Ministra Lorenzin in cui l’Ordine dei medici divenne organo sussidiario dello Stato e cominciò a comportarsi di conseguenza. Il documento della Federazione degli Ordini dei Medici (FNOMCeO) del luglio 2016 (https://portale.fnomceo.it/documento-vaccini/) è un buon esempio di come la categoria medica sia stata costretta a sottostare alla propaganda vaccinale ordita dalle case farmaceutiche e da certa politica. Quella che poi declamava “Vota la scienza”, per intendersi. Tale documento della FNOMCeO, scientificamente lacunoso e del tutto superficiale, è insieme propagandistico e minatorio. Esso inizia con una clamorosa sovrastima dell’efficacia dei vaccini mentre sottostima i problemi e le preoccupazioni espresse da alcuni medici, alcuni dei quali saranno poi radiati, proprio a seguito dell’emanazione delle “Linee-guida”. Il documento rilancia slogan propagandistici privi di spessore scientifico del tipo: “Non bisogna dimenticare che l’incredibile aumento dell’aspettativa di vita in buona salute è dovuto anche all’enorme numero di giovani vite salvate dalla diffusione delle vaccinazioni”. A sostegno di tale idea, di per sé discutibile e indimostrata (persino sul presunto successo della anti- antivaiolosa ci sono grossi dubbi (Bellavite, 2017)), non è citata bibliografia originale ma un libro di Rino Rappuoli (Rappuoli, 2009), guarda caso capo del settore vaccini di Novartis e poi di Glaxo, la casa che produce i vaccini da inoculare nei bimbi italiani. È incredibile che tale libro sia citato senza dichiarare il conflitto d’interessi. La sconfitta della difterite sarebbe uno dei più grandi successi della campagna vaccinale e per dimostrarlo la FNOMCeO cita un lavoro sull’epidemia di difterite in Russia negli anni ’90 (Galazka, 2000), dimenticando di dire che quell’unico caso fu dovuto all’instabilità socio-economica dopo la caduta dell’unione sovietica, al peggioramento delle infrastrutture di salute, alla diminuzione delle condizioni igieniche e della disponibilità di farmaci. In realtà, la difterite non è stata affatto sconfitta dai vaccini (i quali oltretutto non impediscono i contagi) ma dall’igiene e dagli antibiotici (Bellavite, 2018). L’asservimento dei medici emerge da un altro punto critico del documento FNOMCeO, laddove si legge: “solo in casi specifici, quali ad esempio alcuni stati di deficit immunitario, il medico può sconsigliare un intervento vaccinale. Il consiglio di non vaccinarsi nelle restanti condizioni, in particolare se fornito al pubblico con qualsiasi mezzo, costituisce infrazione deontologica”. Qui il testo si fonda equivocamente sulla locuzione "casi specifici", che significa tutto e niente e sul fatto che si fornisce come esempio “alcuni stati di deficit del sistema immunitario”: è persino incredibile che si cita l’immunodeficienza ma si tace sulle allergie e le molte altre ragioni per sconsigliare i vaccini, riconosciute persino dall’ISS (Autori vari, 2009). Cosa significa poi affermare che nelle “restanti condizioni” il consiglio di non vaccinare costituisce infrazione deontologica (leggi: motivo per essere radiato/a)? Quali sono le “restanti condizioni” se le precedenti di riferimento non sono nemmeno esposte? Le restanti condizioni rimangono taciute e ingenerano informazione deficitaria, non corretta, distorcente, omertosa, utilizzabile a piacere dalle commissioni disciplinari. Questa presa di posizione ancora in vigore, che ha dettato i provvedimenti verso medici che avevano espresso opinioni critiche, nega insieme scienza e libertà di pensiero. Come già segnalato, la questione vaccinale è cruciale nella medicina perché è la punta di diamante e la maggiore evidenza dell’intreccio tra cattiva politica, big pharma e informazione asservita, tutto.